Krystal Biotech, Inc. Operating Cash Flow
Krystal Biotech, Inc. (KRYS) reported Operating Cash Flow of $155.17 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-03
- Krystal Biotech, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $74.79M, a 41.84% increase year-over-year.
- Krystal Biotech, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $80.38M, a 159.56% increase year-over-year.
- Krystal Biotech, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $77.51M, a 46.68% increase year-over-year.
- Krystal Biotech, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $39.66M, a 32.62% decline year-over-year.
- Krystal Biotech, Inc. net cash provided by (used in) operating activities for fiscal 2025 was $200.87M, a 62.75% increase from fiscal 2024.
- Krystal Biotech, Inc. net cash provided by (used in) operating activities for fiscal 2024 was $123.42M.
- Krystal Biotech, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$88.80M.
- Krystal Biotech, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$100.57M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $74.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $155.17M 10-Q · filed 2026-08-03 | $232.68M derived: sum of 3 quarters · filed 2026-08-03 | $272.34M derived: sum of 4 quarters · filed 2026-08-03 | |||
| 2026-03-31 | $80.38M 10-Q · filed 2026-05-04 | $157.89M derived: sum of 2 quarters · filed 2026-05-04 | $197.55M derived: sum of 3 quarters · filed 2026-05-04 | $250.28M derived: sum of 4 quarters · filed 2026-08-03 | |||
| 2025-12-31 | $77.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $117.17M derived: sum of 2 quarters · filed 2026-02-17 | $169.90M derived: sum of 3 quarters · filed 2026-08-03 | $200.87M 10-K · filed 2026-02-17 | |||
| 2025-09-30 | $39.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $92.39M derived: sum of 2 quarters · filed 2026-08-03 | $123.36M 10-Q · filed 2025-11-03 | $176.20M derived: sum of 4 quarters · filed 2026-08-03 | |||
| 2025-06-30 | $52.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $83.70M 10-Q · filed 2026-08-03 | $136.54M derived: sum of 3 quarters · filed 2026-08-03 | $195.40M derived: sum of 4 quarters · filed 2026-08-03 | |||
| 2025-03-31 | $30.97M 10-Q · filed 2026-05-04 | $83.81M derived: sum of 2 quarters · filed 2026-05-04 | $142.67M derived: sum of 3 quarters · filed 2026-05-04 | $138.50M derived: sum of 4 quarters · filed 2026-05-04 | |||
| 2024-12-31 | $52.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $111.70M derived: sum of 2 quarters · filed 2026-02-17 | $107.53M derived: sum of 3 quarters · filed 2026-02-17 | $123.42M 10-K · filed 2026-02-17 | |||
| 2024-09-30 | $58.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $54.69M derived: sum of 2 quarters · filed 2025-11-03 | $70.58M 10-Q · filed 2025-11-03 | $63.34M derived: sum of 4 quarters · filed 2026-02-17 | |||
| 2024-06-30 | -$4.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $11.72M 10-Q · filed 2025-08-04 | $4.49M derived: sum of 3 quarters · filed 2026-02-17 | -$16.74M derived: sum of 4 quarters · filed 2026-02-17 | |||
| 2024-03-31 | $15.89M 10-Q · filed 2025-05-06 | $8.66M derived: sum of 2 quarters · filed 2026-02-17 | -$12.57M derived: sum of 3 quarters · filed 2026-02-17 | -$46.76M derived: sum of 4 quarters · filed 2026-02-17 | |||
| 2023-12-31 | -$7.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | -$28.46M derived: sum of 2 quarters · filed 2026-02-17 | -$62.65M derived: sum of 3 quarters · filed 2026-02-17 | -$88.80M 10-K · filed 2026-02-17 | |||
| 2023-09-30 | -$21.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$55.42M derived: sum of 2 quarters · filed 2024-11-04 | -$81.57M 10-Q · filed 2024-11-04 | -$103.90M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2023-06-30 | -$34.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | -$60.35M 10-Q · filed 2024-08-05 | -$82.67M derived: sum of 3 quarters · filed 2025-02-19 | -$102.36M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2023-03-31 | -$26.16M 10-Q · filed 2024-05-06 | -$48.48M derived: sum of 2 quarters · filed 2025-02-19 | -$68.17M derived: sum of 3 quarters · filed 2025-02-19 | -$111.23M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2022-12-31 | -$22.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | -$42.02M derived: sum of 2 quarters · filed 2025-02-19 | -$85.08M derived: sum of 3 quarters · filed 2025-02-19 | -$100.57M 10-K · filed 2025-02-19 | |||
| 2022-09-30 | -$19.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$62.75M derived: sum of 2 quarters · filed 2023-11-06 | -$78.24M 10-Q · filed 2023-11-06 | -$99.14M derived: sum of 4 quarters · filed 2024-02-26 | |||
| 2022-06-30 | -$43.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$58.55M 10-Q · filed 2023-08-07 | -$79.45M derived: sum of 3 quarters · filed 2024-02-26 | -$86.71M derived: sum of 4 quarters · filed 2024-02-26 | |||
| 2022-03-31 | -$15.49M 10-Q · filed 2023-05-08 | -$36.39M derived: sum of 2 quarters · filed 2024-02-26 | -$43.65M derived: sum of 3 quarters · filed 2024-02-26 | -$53.78M derived: sum of 4 quarters · filed 2024-02-26 | |||
| 2021-12-31 | -$20.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$28.16M derived: sum of 2 quarters · filed 2024-02-26 | -$38.28M derived: sum of 3 quarters · filed 2024-02-26 | -$47.94M 10-K · filed 2024-02-26 | |||
| 2021-09-30 | -$7.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$17.38M derived: sum of 2 quarters · filed 2022-11-07 | -$27.04M 10-Q · filed 2022-11-07 | -$35.06M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2021-06-30 | -$10.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$19.78M 10-Q · filed 2022-08-08 | -$27.81M derived: sum of 3 quarters · filed 2023-02-27 | -$34.59M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2021-03-31 | -$9.65M 10-Q · filed 2022-05-09 | -$17.68M derived: sum of 2 quarters · filed 2023-02-27 | -$24.46M derived: sum of 3 quarters · filed 2023-02-27 | -$29.51M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2020-12-31 | -$8.02M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$14.80M derived: sum of 2 quarters · filed 2023-02-27 | -$19.86M derived: sum of 3 quarters · filed 2023-02-27 | -$26.08M 10-K · filed 2023-02-27 | |||
| 2020-09-30 | -$6.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$11.83M derived: sum of 2 quarters · filed 2021-11-08 | -$18.06M 10-Q · filed 2021-11-08 | -$25.06M derived: sum of 4 quarters · filed 2021-11-08 | |||
| 2020-06-30 | -$5.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$11.28M 10-Q · filed 2021-08-09 | -$11.29M 10-Q · filed 2020-08-07 | -$18.28M derived: sum of 3 quarters · filed 2021-08-09 | -$22.55M derived: sum of 4 quarters · filed 2021-08-09 | ||
| 2020-03-31 | -$6.23M 10-Q · filed 2021-05-10 | -$13.23M derived: sum of 2 quarters · filed 2021-05-10 | -$17.49M derived: sum of 3 quarters · filed 2021-05-10 | -$21.70M derived: sum of 4 quarters · filed 2021-05-10 | |||
| 2019-12-31 | -$7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$11.27M derived: sum of 2 quarters · filed 2021-03-01 | -$15.47M derived: sum of 3 quarters · filed 2021-03-01 | -$18.69M 10-K · filed 2021-03-01 | -$18.71M 10-K · filed 2020-03-10 | ||
| 2019-09-30 | -$4.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$8.47M derived: sum of 2 quarters · filed 2020-11-09 | -$11.69M 10-Q · filed 2020-11-09 | -$11.67M 10-Q · filed 2019-11-04 | -$15.21M derived: sum of 4 quarters · filed 2020-11-09 | ||
| 2019-06-30 | -$4.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$7.42M 10-Q · filed 2020-08-07 | -$10.94M derived: sum of 3 quarters · filed 2020-08-07 | -$12.88M derived: sum of 4 quarters · filed 2020-08-07 | |||
| 2019-03-31 | -$3.21M 10-Q · filed 2020-05-04 | -$6.73M derived: sum of 2 quarters · filed 2020-05-04 | -$8.67M derived: sum of 3 quarters · filed 2020-05-04 | -$10.29M derived: sum of 4 quarters · filed 2020-05-04 | |||
| 2018-12-31 | -$3.52M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | -$5.46M derived: sum of 2 quarters · filed 2020-03-10 | -$7.08M derived: sum of 3 quarters · filed 2020-03-10 | -$9.45M 10-K · filed 2020-03-10 | |||
| 2018-09-30 | -$1.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | -$3.56M derived: sum of 2 quarters · filed 2019-11-04 | -$5.93M 10-Q · filed 2019-11-04 | ||||
| 2018-06-30 | -$1.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | -$3.99M 10-Q · filed 2019-08-05 | |||||
| 2018-03-31 | -$2.37M 10-Q · filed 2019-05-07 | ||||||
| 2017-09-30 | -$1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | -$1.76M 10-Q · filed 2018-11-05 | |||||
| 2017-06-30 | -$665.00K 10-Q · filed 2018-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |